IL18-containing 5-gene signature distinguishes histologically identical dermatomyositis and lupus erythematosus skin lesions
Open Access
- 20 August 2020
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (16)
- https://doi.org/10.1172/jci.insight.139558
Abstract
Skin lesions in dermatomyositis (DM) are common, are frequently refractory, and have prognostic significance. Histologically, DM lesions appear similar to cutaneous lupus erythematosus (CLE) lesions and frequently cannot be differentiated. We thus compared the transcriptional profile of DM biopsies with CLE lesions to identify unique features. Type I IFN signaling, including IFN-κ upregulation, was a common pathway in both DM and CLE; however, CLE also exhibited other inflammatory pathways. Notably, DM lesions could be distinguished from CLE by a 5-gene biomarker panel that included IL18 upregulation. Using single-cell RNA-sequencing, we further identified keratinocytes as the main source of increased IL-18 in DM skin. This study identifies a potentially novel molecular signature, with significant clinical implications for differentiating DM from CLE lesions, and highlights the potential role for IL-18 in the pathophysiology of DM skin disease.This publication has 30 references indexed in Scilit:
- Clinical factors associated with cutaneous histopathologic findings in dermatomyositisJournal of Cutaneous Pathology, 2019
- Atopic Dermatitis Is an IL-13–Dominant Disease with Greater Molecular Heterogeneity Compared to PsoriasisJournal of Investigative Dermatology, 2019
- Cutaneous dermatomyositis disease course followed over time using the Cutaneous Dermatomyositis Disease Area and Severity IndexJournal of the American Academy of Dermatology, 2018
- Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappaAnnals Of The Rheumatic Diseases, 2018
- Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositisBritish Journal of Dermatology, 2017
- Polymyositis and dermatomyositis: novel insights into the pathogenesis and potential therapeutic targets.2015
- Type 1 Interferons Inhibit Myotube Formation Independently of Upregulation of Interferon-Stimulated Gene 15PLOS ONE, 2013
- Skin disease in dermatomyositisCurrent Opinion in Rheumatology, 2012
- The interferon‐regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index scoreBritish Journal of Dermatology, 2012
- Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across DiseasesPLOS ONE, 2012